Rhopressa and Conjunctival hyperaemia - a phase IV clinical study of FDA data

Summary:

Conjunctival hyperaemia is reported as a side effect among people who take Rhopressa (netarsudil dimesylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lumigan, and have Glaucoma.

The phase IV clinical study analyzes which people have Conjunctival hyperaemia when taking Rhopressa. It is created by eHealthMe based on reports of 1,507 people who have side effects when taking Rhopressa from the FDA, and is updated regularly.

What is Rhopressa?

Rhopressa has active ingredients of netarsudil dimesylate. eHealthMe is studying from 1,512 Rhopressa users. Check the latest studies of Rhopressa.

What is Conjunctival hyperaemia?

Conjunctival hyperaemia (congestion of conjunctival vessels) is found to be associated with 405 drugs and 620 conditions by eHealthMe. Check the latest studies of Conjunctival hyperaemia.

On Aug, 08, 2026

1,507 people reported to have side effects when taking Rhopressa.
Among them, 253 people (16.79%) have Conjunctival hyperaemia.

Could Rhopressa cause Conjunctival hyperaemia?

Among these 253 people:

How long have people been on Rhopressa when they have Conjunctival hyperaemia? *

Click here to view more results

What is the gender of people who have Conjunctival hyperaemia when taking Rhopressa? *

Click here to view

What is the age of people who have Conjunctival hyperaemia when taking Rhopressa? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Rhopressa and have Conjunctival hyperaemia?

- Check whether Conjunctival hyperaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rhopressa:

Rhopressa (1,512 reports)

Conjunctival hyperaemia treatments and more:

Conjunctival hyperaemia (4,290 reports)

How severe was Conjunctival hyperaemia and when was it recovered:

Conjunctival hyperaemia in Rhopressa

Expand to all the drugs that have ingredients of netarsudil dimesylate:

Conjunctival hyperaemia and drugs with ingredients of netarsudil dimesylate (255 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rhopressa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctival hyperaemia:

Conjunctival hyperaemia (405 drugs)

Browse all the conditions that are associated with Conjunctival hyperaemia:

Conjunctival hyperaemia (620 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on netarsudil dimesylate (the active ingredients of Rhopressa) and Rhopressa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.